Abstract on the study accepted at the 2019 ICML Meeting
IMV Inc. (Nasdaq: IMV; TSX: IMV), the clinical stage immuno-oncology
corporation, today announced that the 2019 International
Conference on Malignant Lymphoma (ICML) will publish an abstract on
the company’s combination immunotherapy trial titled, “Phase 2 Study:
DPX-Survivac with Intermittent Low Dose Cyclophosphamide and
Pembrolizumab in Patients with recurrent/refractory Diffuse Large B-Cell
Lymphoma – The SPiReL trial.”
“DLBCL is our first indication for DPX-Survivac in combination with
Merck’s’ Keytruda® (pembrolizumab) and we have been encouraged by the previously
announced early data in this patient population with rapidly
progressing cancer and short life expectancy,” said Frederic
Ors, Chief Executive Officer at IMV. “Given the high level of unmet
need in recurrent/refractory DLBCL, we look forward to working with our
partners at Sunnybrook Research Institute to provide an update on this
important program.”
ICML will publish the full trial-in-progress abstract on June 12,
2019 via the 15-ICML ABSTRACT BOOK, a supplement to Hematological
Oncology. IMV will provide an update on the Phase 2 clinical data
related to this study at that time.
About the SPiReL Study
SPiReL (DPX-Survivac with Low Dose
Cyclophosphamide administered with Pembrolizumab
in Patients with persistent or Recurrent/refractory
Diffuse Large B-Cell Lymphoma) is a Phase 2
non-randomized, multi-centre, open-label study. Primary Investigator Neil
Berinstein, MD, Affiliate Scientist, Sunnybrook Research Institute,
Professor of Medicine/Immunology, University of Toronto, is leading
the trial, which is expected to enroll 25 evaluable participants whose
recurrent DLBCL expresses survivin, a tumor antigen expressed in
approximately 60 percent of DLBCL patients. The study’s primary endpoint
is to document the objective response rate. Secondary objectives include
measuring tumor regression, and documenting the toxicity profile and
durations of response. In addition, researchers will perform analyses to
assess circulating antigen specific immune responses and changes in
tumor-infiltrating T cell immune responses within the tumor
microenvironment. Investigators also plan to assess potential biomarkers
of immune and clinical response.
About ICML
The International Conference on Malignant Lymphoma (ICML) is focused on
the scientific community involved in the study and treatment of lymphoid
neoplasms. The main aim of ICML is to facilitate the presentation of the
most recent data—basic, translational and clinical—on lymphoma and
encourage the discussion among hematologists, clinical oncologists,
radiation oncologists, pediatricians, pathologists, and leading
researchers from all over the world.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated to
making immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious diseases. IMV
is pioneering a new class of immunotherapies based on the Company’s
proprietary drug delivery platform. This patented technology leverages a
novel mechanism of action that enables the programming of immune cells in
vivo, which are aimed at generating powerful new synthetic
therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T
cell-activating immunotherapy that combines the utility of the platform
with a target: survivin. IMV is currently assessing DPX-Survivac as a
monotherapy in advanced ovarian cancer, as well as a combination therapy
in multiple clinical studies with Merck. Connect at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses activities or
developments that we expect to occur in the future is forward-looking
information. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. In the press
release, such forward-looking statements include, but are not limited
to, statements regarding the FDA potentially granting accelerated
regulatory approval of DPX-Survivac. However, they should not be
regarded as a representation that any of the plans will be achieved.
Actual results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials and the
receipt and timely receipt of all regulatory approvals. IMV Inc. assumes
no responsibility to update forward-looking statements in this press
release except as required by law. These forward-looking statements
involve known and unknown risks and uncertainties and those risks and
uncertainties include, but are not limited to, our ability to access
capital, the successful and timely completion of clinical trials, the
receipt of all regulatory approvals and other risks detailed from time
to time in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking statements
and are encouraged to read IMV’s continuous disclosure documents,
including its current annual information form, as well as its audited
annual consolidated financial statements which are available on SEDAR at www.sedar.com and
on EDGAR at www.sec.gov/edgar.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190503005183/en/
Copyright Business Wire 2019